Starting Dose of Diltiazem for Angina
For immediate-release diltiazem, start with 30 mg four times daily; for extended-release formulations, start with 120 mg once daily. 1, 2, 1, 3
Dosing Recommendations by Formulation
Immediate-Release Diltiazem
- Starting dose: 30 mg four times daily (120 mg total daily dose)
- Usual dose range: 30-90 mg four times daily
- Maximum: 360 mg/day in divided doses 1, 2, 1, 3
Extended-Release Diltiazem
- Starting dose: 120 mg once daily
- Usual dose range: 120-360 mg once daily
- Can be titrated upward based on response 1, 2, 1, 3
Titration Strategy
Start low and titrate upward based on symptom control and tolerability. Research demonstrates dose-dependent improvements in exercise tolerance and angina frequency 4, 5, 6, 7. Studies show:
- 120 mg/day provides modest benefit
- 240 mg/day shows significant improvement
- 360 mg/day provides optimal antianginal efficacy with the best reduction in anginal attacks and nitroglycerin consumption 5, 6, 7
The dose-response relationship is progressive, with incremental improvements as you increase from 120 mg to 240 mg to 360 mg daily 4, 5.
Clinical Context and Contraindications
Avoid diltiazem in patients with:
- Pulmonary edema or severe left ventricular dysfunction 1, 3
- Second- or third-degree AV block (without pacemaker)
- Sick sinus syndrome (without pacemaker)
- Hypotension 1, 3
Exercise caution when combining with beta-blockers, as synergistic effects on AV conduction and left ventricular function can occur 1. However, this combination can be used carefully when needed for refractory symptoms.
Practical Considerations
For converting from immediate-release to extended-release: Use mg-for-mg conversion or round up to the next available dose strength 8. This approach maintains efficacy while improving compliance with once-daily dosing.
Timing matters for extended-release formulations: Evening dosing (at bedtime) may provide superior protection during the high-risk morning hours (7-11 AM) compared to morning dosing, with a 4-fold greater placebo-adjusted improvement in exercise tolerance during this period 9.
The evidence base for diltiazem in angina is substantial, with demonstrated efficacy in reducing reinfarction and refractory angina without increasing mortality 1. Unlike immediate-release nifedipine, diltiazem does not require concomitant beta-blocker therapy and can be used as monotherapy 1, 3.